These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26153241)

  • 81. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC
    Br Med Bull; 2009; 90():71-84. PubMed ID: 19474056
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Ivabradine in acute coronary syndromes: Protection beyond heart rate lowering.
    Niccoli G; Borovac JA; Vetrugno V; Camici PG; Crea F
    Int J Cardiol; 2017 Jun; 236():107-112. PubMed ID: 28256323
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina.
    Amosova E; Andrejev E; Zaderey I; Rudenko U; Ceconi C; Ferrari R
    Cardiovasc Drugs Ther; 2011 Dec; 25(6):531-7. PubMed ID: 21830063
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Ivabradine in coronary heart disease: experimental and clinical pharmacology].
    Pathak A; Berdeaux A; Mulder P; Thuillez C
    Therapie; 2010; 65(5):483-9. PubMed ID: 21144484
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Ivabradine: Current and Future Treatment of Heart Failure.
    Thorup L; Simonsen U; Grimm D; Hedegaard ER
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):89-97. PubMed ID: 28371247
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L
    Eur J Heart Fail; 2010 Jan; 12(1):75-81. PubMed ID: 19892778
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
    Komajda M; Tavazzi L; Francq BG; Böhm M; Borer JS; Ford I; Swedberg K;
    Eur J Heart Fail; 2015 Dec; 17(12):1294-301. PubMed ID: 26377342
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy.
    Böhm M; Borer JS; Camm J; Ford I; Lloyd SM; Komajda M; Tavazzi L; Talajic M; Lainscak M; Reil JC; Ukena C; Swedberg K
    Eur J Heart Fail; 2015 May; 17(5):518-26. PubMed ID: 25801408
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Ivabradine in combination with Beta-blockers in patients with chronic stable angina after percutaneous coronary intervention.
    Werdan K; Ebelt H; Nuding S; Höpfner F; Stöckl G; Müller-Werdan U
    Adv Ther; 2015 Feb; 32(2):120-37. PubMed ID: 25687888
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A genetic model of ivabradine recapitulates results from randomized clinical trials.
    Legault MA; Sandoval J; Provost S; Barhdadi A; Lemieux Perreault LP; Shah S; Lumbers RT; de Denus S; Tyl B; Tardif JC; Dubé MP
    PLoS One; 2020; 15(7):e0236193. PubMed ID: 32692755
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Stable coronary artery disease: are there therapeutic benefits of heart rate lowering?
    Tanna MS; Messerli FH; Bangalore S
    J Hypertens; 2019 Jun; 37(6):1112-1118. PubMed ID: 30676481
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The challenges with chronic angina.
    Ohman EM; Alexander KP
    N Engl J Med; 2014 Sep; 371(12):1152-3. PubMed ID: 25176137
    [No Abstract]   [Full Text] [Related]  

  • 93. Does Ivabradine SIGNIFY Improvements in Quality of Life?
    Norris CM; Bainey KR
    Circ Cardiovasc Qual Outcomes; 2016 Jan; 9(1):5-6. PubMed ID: 26696612
    [No Abstract]   [Full Text] [Related]  

  • 94. [Heart Rate and Cardioprotection: New Data and Perspectives].
    Kanorskii SG
    Kardiologiia; 2015; 55(8):55-61. PubMed ID: 26761974
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Ivabradine in Coronary Heart Disease-The Emperor Has No Clothes.
    Messerli FH; Rimoldi SF; Bangalore S
    Am J Cardiol; 2017 Aug; 120(3):e15. PubMed ID: 27349902
    [No Abstract]   [Full Text] [Related]  

  • 96. Ivabradine and the SIGNIFY conundrum.
    Beltrame JF
    Eur Heart J; 2015 Dec; 36(46):3297-9. PubMed ID: 26264551
    [No Abstract]   [Full Text] [Related]  

  • 97. Dose-dependent effects of ivabradine on heart rate during maximal efforts in a woman with permanent atrial fibrillation.
    Fossati C; Volterrani M; Punzo N; Campolongo G; Cascelli G; Caminiti G
    Int J Cardiol; 2017 Nov; 247():37. PubMed ID: 28916075
    [No Abstract]   [Full Text] [Related]  

  • 98. Corrigendum to "Addition of ivabradine to betablockers in patients with atrial fibrillation: Effects on heart rate and exercise tolerance" [Int. J. Cardiol. 202 (2016) 76-77].
    Caminiti G; Fossati C; Rosano G; Volterrani M
    Int J Cardiol; 2016 Nov; 223():1077. PubMed ID: 27614572
    [No Abstract]   [Full Text] [Related]  

  • 99. Can ivabradine still be used in clinical practice after the 'SIGNIFY' trial?
    Reil JC; Bohm M
    Eur Heart J; 2015 Jun; 36(22):1353-4. PubMed ID: 26251857
    [No Abstract]   [Full Text] [Related]  

  • 100. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study.
    Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
    Eur Heart J; 2015 Dec; 36(46):3291-6. PubMed ID: 26385957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.